Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

Written by Emily J. Thompson, Senior Investment Analyst

APTO%

Source: Newsfilter

Updated: Apr 01 2025

0mins

Source: Newsfilter

Delisting from Nasdaq: Aptose Biosciences has been determined by the Nasdaq Hearings Panel to delist its common shares due to non-compliance with the equity requirement, effective April 2, 2025, after failing to regain compliance by the March 31 deadline.
Future Plans: The company plans to review options including an appeal of the delisting decision while continuing to execute its business strategy and aims to list on a U.S. national securities exchange in the future.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Micron Technology (MU) to Acquire Taiwanese Chip Fab for $1.8B

UPS Stock Rises Nearly 30% Ahead of Earnings Report on January 27

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch